• VolitionRx Limited Announces Third Quarter 2018 Financial Results and Business Update

  • VolitionRx Limited Schedules Third Quarter 2018 Earnings Conference Call and Business Update

  • VolitionRx Limited to Expand its Nu.Q(TM) Trials to Veterinary Diagnostics

  • VolitionRx Limited Releases Video Featuring Interviews with its Scientific Advisory Board

  • VolitionRx Limited Announces Second Quarter 2018 Financial Results and Business Update

  • Preliminary Data from Study Demonstrates 94% Accuracy in Detecting Aggressive Prostate Cancer

  • VolitionRx Limited Announces Completion of Sample Collection in Endometriosis Study

  • VolitionRx Announces $9 Million Private Placement

  • VolitionRx Limited Schedules Second Quarter 2018 Earnings Conference Call and Business Update

  • VolitionRx's First Research Use Only Product Is "On-The-Shelf" Today

  • Volition Extends Global Reach of its Clinical Trial Program

  • Volition Secures Additional $700,000 Non-Dilutive Funding from the Walloon Region

  • VolitionRx Limited to Attend the Bank of America Merrill Lynch 2018 Health Care Conference from May 15-17, 2018

  • VolitionRx Limited Announces First Quarter 2018 Financial Results and Business Update

  • VolitionRx Signs a Global Sales and Distribution Agreement with Active Motif for its new RUO kits

  • VolitionRx Limited Schedules First Quarter 2018 Earnings Conference Call and Business Update

  • VolitionRx Announces Closing of $8.4 Million Public Offering of Common Stock

  • VolitionRx Announces Pricing of $8.4 Million Public Offering of Common Stock

  • VolitionRx Announces Proposed Underwritten Public Offering of Common Stock

  • VolitionRx Appoints Harvard Professor, Dr. Lee-Jen Wei to Its Scientific Advisory Board

  • VolitionRX Limited Announces Full Fiscal Year 2017 Financial Results and Business Update

  • VolitionRx Limited Schedules Full Year 2017 Earnings Conference Call and Business Update

  • VolitionRx Limited Announces Interim Results from 680-Subject Clinical Trial in Colorectal Cancer

  • VolitionRX Announces the Successful Conclusion of the Logistics and Pathway Design Study Conducted in Denmark.

  • VolitionRx Limited Releases Letter to Shareholders Including Status Update on Key Clinical Milestone

arrow-downarrow-leftarrow-rightarrowchevron-downcircle-link--redcircle-linkcloseplayplus